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Listeria monocytogenes (LM) infection is rare, but can cause severe 
infection in pregnant women and during the neonatal period.[1] LM 
is inherently resistant to some broad-spectrum antibiotics, including 
third-generation cephalosporins (e.g. ceftriaxone), which are 
commonly used as first-line antibiotics to treat suspected infection 
in the community.[2] For this reason, ampicillin is recommended 
for the empirical treatment of neonatal sepsis (ampicillin and 
gentamicin)[3] and neonatal meningitis (ampicillin and a third-
generation cephalosporin). Most treatment protocols recommend 
that ampicillin be added to a third-generation cephalosporin for the 
treatment of suspected serious bacterial infection in infants aged 
<3 months presenting with a fever, to ensure that cephalosporin-
resistant organisms, especially LM, are treated.[4]
Two distinct clinical syndromes are seen in neonatal listeriosis. 
Early-onset infection in the first 7 days of life is associated with 
overwhelming sepsis and a high mortality rate. Late-onset infection 
occurring between 7 and 90 days has a lower mortality, but ~94% 
of patients have meningitis,[5] which is associated with poor 
neurodevelopmental outcomes.[6]
Although the majority of neonatal cases present in the first 7 days 
of life, many guidelines still recommend additional LM cover up to 
3 months of age.[1] A case series from the UK reported 362 infant 
cases of LM from 1970 to 2013, including sepsis and meningitis. [7] 
Of all cases of LM, 97% occurred in the first 90 days of life; of those 
occurring within the first 90 days, 99% presented in the first 30 days. 
Only 5  cases occurred in infants aged between 31 and 90 days in 
this 24-year period. Similarly, in a recent international review of LM 
infections, only 5 (of a total of 524) cases of LM were reported in infants 
aged 1 - 3 months.[1] There was a marked decrease in the incidence of 
pregnancy-related listeriosis in France from 1984 to 2006 related 
to the implementation of specific LM control measures at the food 
production level.[8] Data from 2006 to 2012 in the USA documented 
181 cases of bacteraemia with no cases of LM in infants. [9] The World 
Health Organization recommends initial antibiotic therapy with a 
penicillin and an aminoglycoside or a third-generation cephalosporin 
for young infants (<60 days of age).[10] Current South African (SA) 
recommended guidelines for treatment of acute bacterial meningitis 
include addition of empirical ampicillin for infants aged <1 month 
of age until LM is excluded,[11] but in a number of centres, including 
ours, ampicillin is still added empirically to the treatment of suspected 
sepsis or meningitis in infants aged <2 months.
There are limited published data on LM from SA. Two studies 
looking at paediatric LM were published between 25 and 50 years 
ago. A study done at Baragwanath Hospital in Johannesburg from 
August 1977 to April 1978 identified 14 cases of LM, 9 in neonates. 
All the neonates were aged <2 weeks at presentation. Four died, all 
within 3 days of birth or hospital admission.[12]
During a 10-year period at King Edward VIII Hospital in Durban 
from 1981 to 1990, 9 cases of LM were identified; 6 patients were 
children, of whom 5 were neonates. Three infants died.[13]
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Background. Ampicillin to treat Listeria monocytogenes (LM) infection is empirically added to the treatment of infants (<3 months) with 
suspected sepsis or meningitis.
Objectives. In view of limited LM cases, the paucity of South African (SA) data and an ampicillin shortage, our objective was to describe 
the occurrence of LM infections at Tygerberg Hospital (TBH), Cape Town, with the aim of rationalising the paediatric antibiotic policy.
Methods. An 11-year (2006 - 2016) retrospective descriptive study of children (<13 years) from TBH and referral hospitals with a positive 
blood or cerebrospinal fluid (CSF) culture for LM was conducted.
Results. Of 26 children with positive cultures for LM, 23 (88.5%) were <3 months of age; all were <10 days old. Approximately half (56.5%, 
13/23) were born at or referred to TBH. Presentation was on the day of delivery in 46.2% (6/13), 92.3% were admitted to the neonatal 
intensive care unit (NICU), and 61.5% (8/13) died. Neonates treated at peripheral hospitals were statistically more likely than those treated 
at TBH to have a CSF culture obtained (90.0% v. 30.8%; p=0.005), and had higher platelet counts (239 × 109/L v. 107 × 109/L; p=0.004), lower 
C-reactive protein levels (64 mg/L v. 137 mg/L; p=0.013) and a lower mortality rate (0% v. 61.5%; p=0.002). The incidence of LM at TBH 
was 0.04/1 000 live births and 2.3/1 000 NICU admissions.
Conclusions. As in other countries, the local neonatal LM incidence is low. Neonates present in the first week of life with severe disease and 
a high mortality rate. These data support a change in antibiotic policy, in keeping with international guidelines, limiting empirical ampicillin 
prescription to infants <1 month of age.
S Afr Med J 2018;108(11):937-943. DOI:10.7196/SAMJ.2018.v108i11.13212
938       November 2018, Vol. 108, No. 11
RESEARCH
An isolated outbreak occurred in the 
Western Cape Province in 2015, where 
a total of 7 cases were documented at a 
tertiary hospital. [14] One blood culture from 
a pregnant woman and two cultures from 
neonates, both 1 day old, isolated LM.[15]
A systematic review of neonatal meningitis 
in developing countries showed that LM was 
seldom reported in the developing world, 
with Gram-negative organisms being more 
common. This was thought to be due to 
low availability of common potential food 
contamination sources.[16]
The addition of ampicillin to a third-
generation cephalosporin for suspected 
neonatal sepsis and meningitis in neonates 
and infants aged <90 days seems to be 
appropriate, as most studies[4,7] show 
that LM is rare after 30 days of age. The 
question remains whether the empirical 
addi tion of ampicillin to a third-generation 
cephalosporin cannot be further restricted. 
There is limited evidence to determine the 
optimal age at which ampicillin therapy 
is no longer needed as a part of empirical 
antibiotic regimens.[4] Data from developed 
countries suggest that empirical ampicillin 
therapy is no longer needed after 1 month 
of age,[17] and there are limited data in Africa 
to support this practice; however, we have 
no data regarding the prevalence of LM 
infection at our institution.
In the first half of 2015, we experienced a 
shortage of ampicillin at Tygerberg Hospital 
(TBH), such that its use was restricted to 
a named-patient basis only and empirical 
cover for fever without a source was changed 
to a third-generation cephalosporin, even 
in the absence of meningitis (unpublished 
data). This raised a concern about missing 
LM sepsis and meningitis in neonates and 
young infants.
In view of the limited number of LM cases 
seen in other countries and the limited SA 
data available, we reviewed paediatric and 
neonatal cases of LM at TBH to describe 
the demographics, clinical presentation and 
outcome of these patients. This may help 
provide evidence upon which to rationalise 
local use of ampicillin in the future, especially 
in view of the recent ampicillin shortages.
Methods
Study setting
TBH provides secondary- and tertiary-level 
care to residents of the Eastern Metro region of 
Cape Town. It serves surrounding subdistricts 
as well as certain areas outside the Cape 
Metro region (e.g. Winelands). Residents of 
Metro West are served by a tertiary paediatric 
hospital as well as two maternity units 
providing secondary- and tertiary-level care.
Case identification
A retrospective descriptive study was con-
ducted from 1 January 2006 to 31 Dec ember 
2016, to identify patients aged <13 years with 
laboratory-confirmed LM bacter aemia or 
meningitis. A review of the National Health 
Laboratory Service (NHLS) database was 
undertaken to identify all positive cerebro-
spinal fluid (CSF) and blood cultures pro-
cessed by the NHLS at TBH. Data were 
also obtained from the NHLS central data 
warehouse, which processes data from the 
Eastern and Western metro. All positive 
cultures from children <13 years of age and 
pregnant women were included in the analysis.
Data collection
The folders of children with positive cul-
tures managed at TBH were reviewed and 
data were entered anonymously onto a data 
collection form.
Demographic data collected included 
date of birth, gender, dates of admission 
and discharge and residential area. Clinical 
data included gestational age, birth weight, 
maternal illness, admission vital signs and 
initial clinical presentation as well as clinical 
outcome (discharged or died). Laboratory 
data included the admission full blood 
count and C-reactive protein (CRP) level, 
lumbar puncture results if applicable, and 
HIV status. Microbiological data included 
date of sample, site of sample (blood or CSF) 
and antibiotic sensitivity. Empirical use of 
antibiotic/s at initiation was noted.
For positive cultures from children 
not referred to TBH, data on age, date 
of admission and discharge, residential 
area and outcome were collected from the 
Western Cape hospital information system.
For pregnant women, data were collected 
on age, residential area, antepartum illness 
(including fever and preterm prelabour 
rupture of the membranes (PPROM)), 
gestation, date of initiating antibiotics, date 
of birth of the baby and outcome of the baby.
To calculate LM incidence, total numbers 
of admissions and live births were obtained 
from the TBH Department of Paediatrics and 
Child Health annual reports (unpublished 
data), Saving Babies reports (Perinatal 
Problem Identification Programme)[18-20] and 
personal hospital sources for the Winelands 
and Overberg regions.
Data analysis, statistics and ethics 
approval
Data were analysed using Stata version 14.2 
(StataCorp, USA). Continuous variables 
were summarised using medians and ranges, 
and frequencies and associated percentages 
were used to describe categorical variables. 
Association between categorical variables was 
assessed using the χ2 distribution or Fisher’s 
exact test. Differences between distributions 
of white cell counts by group were evaluated 
using the Wilcoxon rank-sum test.
The study was approved by the Stellen-
bosch University Health Research Ethics 
Committee (ref. no. S16/02/033).
Results
There were a total of 51 positive cultures for 
LM at the TBH laboratory over the 11-year 
study period. Half of the patients (26/51, 
51.0%) were children aged <13 years and 
were included in our analysis; of these, 23/26 
(88.5%) were <3 months of age. There were 
no children aged 1 - 3 months with positive 
cultures during this period. Of the patients, 
Cultures positive for LM
N=51
Age ≥13 years
n=25
Age <13 years
n=26
Maternal
n=2
'Other' adults
n=22
Age >3 months
n=3
Age ≤3 months
n=23
Case 1: VPS – meningitis
Case 2: Near-drowning
Case 3: Previously healthy 
10-year-old with meningitis
1 - 3 months
n=0
≤1 month
n=23
Managed outside TBH
n=10
Managed at TBH
n=13
≤7 days old
n=10
>7 days old
n=0
≤7 days old
n=11
>7 days old
n=2
Fig. 1. Patients with cultures (blood and cerebrospinal fluid) positive for LM during the period 1 January 
2006 - 31 December 2016. (LM = Listeria monocytogenes; VPS = ventriculoperitoneal shunt; TBH = 
Tygerberg Hospital.)
939       November 2018, Vol. 108, No. 11
RESEARCH
Ta
bl
e 1
. C
lin
ic
al
 d
et
ai
ls 
an
d 
ou
tc
om
es
 o
f n
eo
na
te
s w
ith
 L
ist
er
ia
 m
on
oc
yt
og
en
es
 in
fe
ct
io
n 
m
an
ag
ed
 at
 T
yg
er
be
rg
 H
os
pi
ta
l
Age
(days)
Area
Inborn/
transfer in
BW (g) and 
GA (weeks)
Antenatal care
In hospital/
from home
Sex
HIV exposure
Clinical 
picture
Level of care
Resp. support
Inotropes
Year
Length of stay 
(days)
CSF obtained/
culture result
Outcome 
(A or D), 
neuroimaging 
finding
Empirical 
cover
0
O
ve
rb
er
g
Tr
an
sfe
r i
n
1 
10
0/
28
Y
In
 h
os
pi
ta
l
M
Ex
po
se
d
Re
sp
ira
to
ry
 d
ist
re
ss
, 
ap
no
ea
, h
yp
ot
he
rm
ia
N
IC
U
IP
PV
N
20
16
15
N
A
/g
r 2
 IV
H
Y
0
Ea
ste
rn
Tr
an
sfe
r i
n
1 
80
0/
31
N
In
 h
os
pi
ta
l
M
U
ne
xp
os
ed
D
ep
re
ss
ed
 L
O
C,
 fu
ll 
fo
nt
an
el
le,
 re
sp
ira
to
ry
 
di
str
es
s, 
ap
no
ea
, 
hy
po
th
er
m
ia
N
IC
U
H
FO
V
Y
20
16
0
N
D  
N
10
Ea
ste
rn
Tr
an
sfe
r i
n
2 
40
0/
40
N
H
om
e, 
vi
a 
EU
F
U
ne
xp
os
ed
D
ep
re
ss
ed
 L
O
C,
 
re
sp
ira
to
ry
 d
ist
re
ss
, 
ap
no
ea
, h
yp
ot
he
rm
ia
, 
hy
po
gl
yc
ae
m
ia
N
IC
U
IP
PV
Y
20
15
2
N
D
Y
3
W
in
el
an
ds
Tr
an
sfe
r i
n
2 
20
0/
30
Y
H
om
e, 
vi
a 
EU
M
U
ne
xp
os
ed
D
ep
re
ss
ed
 L
O
C,
 
re
sp
ira
to
ry
 d
ist
re
ss
, f
ul
l 
fo
nt
an
el
le,
 ra
sh
, j
au
nd
ic
e, 
ap
no
ea
, h
yp
og
ly
ca
em
ia
, 
hy
po
th
er
m
ia
N
IC
U
H
FO
V
Y
20
15
0
N
D
Y
0
W
in
el
an
ds
Tr
an
sfe
r i
n
1 
60
0/
33
N
In
 h
os
pi
ta
l
M
U
ne
xp
os
ed
Re
sp
ira
to
ry
 d
ist
re
ss
, 
ap
no
ea
, r
as
h,
 
hy
po
gl
yc
ae
m
ia
, 
ta
ch
yc
ar
di
a, 
hy
po
te
ns
io
n
N
IC
U
IP
PV
Y
20
15
36
N
A
/IV
H
 a
nd
 
hy
dr
oc
ep
ha
lu
s
 
Y
2
N
or
th
er
n
Tr
an
sfe
r i
n
2 
30
0/
35
Y
In
 h
os
pi
ta
l
F
U
ne
xp
os
ed
 
Ra
sh
, a
pn
oe
a
N
IC
U
H
FO
V
Y
20
15
2
N
D
Y
1
O
ve
rb
er
g
Tr
an
sfe
r i
n
2 
60
0/
35
Y
In
 h
os
pi
ta
l
M
U
ne
xp
os
ed
Re
sp
ira
to
ry
 d
ist
re
ss
, 
ja
un
di
ce
N
IC
U
IP
PV
N
20
13
12
N
A
N
0
Ty
ge
rb
er
g
In
bo
rn
1 
50
0/
33
Y
In
 h
os
pi
ta
l 
F
U
ne
xp
os
ed
Re
sp
ira
to
ry
 d
ist
re
ss
, r
as
h,
 
hy
po
gl
yc
ae
m
ia
N
IC
U
H
FO
V
Y
20
12
2
Y/
po
sit
iv
e
D
Y
2
N
or
th
er
n
Tr
an
sfe
r i
n
1 
20
0/
32
Y
In
 h
os
pi
ta
l
M
Ex
po
se
d
D
ep
re
ss
ed
 L
O
C,
 
re
sp
ira
to
ry
 d
ist
re
ss
N
IC
U
IP
PV
Y
20
12
20
Y/
ne
ga
tiv
e
A
/g
r 1
 IV
H
Y
0
Ty
ge
rb
er
g
In
bo
rn
1 
20
0/
32
U
nk
no
w
n
In
 h
os
pi
ta
l
F
Ex
po
se
d
Re
sp
ira
to
ry
 d
ist
re
ss
H
CU
nC
PA
P
N
20
10
19
Y/
po
sit
iv
e
A
U
nk
no
w
n
3
N
or
th
er
n
Tr
an
sfe
r i
n
 2
 4
00
/3
6
Y
H
om
e, 
vi
a 
EU
F
Ex
po
se
d
D
ep
re
ss
ed
 L
O
C,
 fu
ll 
fo
nt
an
el
le,
 ja
un
di
ce
, 
ap
no
ea
N
IC
U
IP
PV
Y
20
09
4
Y/
ne
ga
tiv
e
D
/h
yd
ro
ce
ph
al
us
Y
9
W
in
el
an
ds
Tr
an
sfe
r i
n
2 
50
0/
35
U
nk
no
w
n
H
om
e, 
vi
a 
EU
F
U
ne
xp
os
ed
D
ep
re
ss
ed
 L
O
C,
 ap
no
ea
N
IC
U
IP
PV
Y
20
07
5
N
D
/h
yd
ro
ce
ph
al
us
N
0
Ea
ste
rn
In
bo
rn
2 
50
0/
36
Y
In
 h
os
pi
ta
l
F
U
ne
xp
os
ed
D
ep
re
ss
ed
 L
O
C,
 
re
sp
ira
to
ry
 d
ist
re
ss
, 
ap
no
ea
, h
yp
og
ly
ca
em
ia
N
IC
U
H
FO
V
Y
20
06
5
N
D
Y
BW
 =
 b
irt
h 
w
ei
gh
t; 
G
A
 =
 g
es
ta
tio
na
l a
ge
; R
es
p.
 =
 re
sp
ira
to
ry
; C
SF
 =
 ce
re
br
os
pi
na
l f
lu
id
; D
 =
 d
ea
d;
 A
 =
 al
iv
e; 
gr
 =
 g
ra
de
; I
V
H
 =
 in
tr
av
en
tr
ic
ul
ar
 h
ae
m
or
rh
ag
e; 
Y 
= 
ye
s; 
N
 =
 n
o;
 M
 =
 m
al
e; 
F 
= 
fe
m
al
e; 
N
IC
U
 =
 n
eo
na
ta
l i
nt
en
siv
e c
ar
e u
ni
t; 
H
CU
 =
 h
ig
h-
ca
re
 u
ni
t; 
 
IP
PV
 =
 in
te
rm
itt
en
t p
os
iti
ve
-p
re
ss
ur
e v
en
til
at
io
n;
 H
FO
V
 =
 h
ig
h-
fre
qu
en
cy
 o
sc
ill
at
or
y 
ve
nt
ila
tio
n;
 n
CP
A
P 
= 
na
sa
l c
on
tin
uo
us
 p
os
iti
ve
 ai
rw
ay
 p
re
ss
ur
e; 
LO
C 
= 
le
ve
l o
f c
on
sc
io
us
ne
ss
; E
U
 =
 em
er
ge
nc
y 
un
it.
940       November 2018, Vol. 108, No. 11
RESEARCH
13/23 (56.5%) were managed at TBH and 10/23 (43.5%) at peripheral 
hospitals (Fig. 1).
One folder was unavailable for review, but laboratory and admis-
sion and discharge data were entered for this neonate.
The clinical details and outcomes of the neonates born at or 
referred to TBH are summarised in Table 1. Cases were evenly 
distributed over the 11 years, except for 2015 when there were 
4 cases. Only 3/13 (23.1%) were born at TBH. There was an equal 
sex distribution (6/13 (46.2%) male). The majority (12/13, 92.3%) 
of neonates were born preterm (<37 weeks’ gestation), the median 
birth weight was 2.2 kg (interquartile range (IQR) 1.5 - 2.4), and 4/13 
(30.8%) were HIV-exposed; of these, 1 was HIV-infected (positive 
HIV polymerase chain reaction). The majority of the mothers (8/11, 
72.7%) had attended antenatal care during their pregnancy. Eleven 
neonates (84.6%) presented within 7 days after birth, nearly half (6/13, 
46.2%) on the day of delivery. Neonates presented with severe disease; 
9/13 (69.2%) presented with respiratory distress and/or apnoea and 
7/13 (53.8%) with a depressed level of consciousness. Other features 
noted on admission included a rash (4/13, 30.8%), jaundice (3/13, 
23.1%), a full fontanelle (3/13, 23.1%) and hypoglycaemia (blood 
glucose <2.6 mmol/L) (5/13, 38.5%). The 4/13 neonates (30.8%) who 
presented with hypothermia (temperature <35.5oC) were transferred 
from peripheral hospitals. Most patients (12/13, 92.3%) required 
intensive care admission and invasive ventilation. The remaining 
patient required nasal continuous positive airway pressure therapy 
and high-care admission. Ten neonates (76.9%) needed inotropic 
support.
Eight neonates (61.5%) died, with their median length of stay being 
2.5 days (IQR 1.5 - 4.3). Of the 13 patients, 3 had hydrocephalus, 
presumed to be secondary to Listeria meningitis. The median length 
of stay for the neonates who were discharged alive was 19 days 
(IQR 15 - 20). Of the 13 patients, 9 (69.2%) received empirical Listeria 
cover.
Table 2 sets out the laboratory data for the neonates described in 
Table 1. Of the 13 patients, 11 (84.6%) had an elevated CRP level 
(>10  mg/L) on presentation. Only 4/13 (30.8%) had a CSF sample 
taken; of the samples, 2/4 (50.0%) cultured LM.
CSF findings revealed a lymphocyte predominance, normal 
glucose and mildly elevated CSF protein.
Table 3 shows the comparison between the neonates managed 
at TBH and those managed outside TBH. Both groups of neonates 
presented early (p=0.66) and within 10 days of birth.
The neonates managed at peripheral hospitals were more likely 
than the TBH group to have a CSF sample obtained for culture 
(p=0.005). Although the infants managed at TBH were more likely 
to have a positive CSF culture, this difference did not reach statistical 
significance. White cell counts and haemoglobin concentrations were 
similar between the two groups (p=0.952 and p=0.072, respectively), 
but the median platelet count was significantly lower (107 × 109/L 
(IQR 66 - 190) v. 239 × 109/L (IQR 167 - 254); p=0.004) and the 
CRP level significantly higher (137 mg/L (IQR 107 - 156) v. 64 mg/L 
(IQR  36 - 97); p=0.01) in the TBH group. The neonates managed 
at TBH (including those who died) had a shorter duration of stay 
(5.0 days (IQR 2 - 15) v. 20.5 days (IQR 14.5 - 23); p=0.013) and 
significantly higher mortality (61.5% v. 0%; p=0.002). For those who 
survived, the duration of stay was similar at the two locations (19 days 
(IQR 15 - 20) v. 20.5 days (IQR 14.5 - 23); p=0.9).
There were too few patients to statistically compare those with 
LM born at TBH with those transferred in from outside hospitals. 
Key findings are tabulated in Table 4. The two groups appeared to be 
similar with regard to clinical presentation and disease severity, but 
neonates born at TBH had a lower median glucose level on admission 
and a lower CRP level compared with the other group.
There were 25 cases of LM in individuals ≥13 years of age. Only 
3/25 (12.0%) occurred in pregnant women, in 2009, 2015 and 2016, 
respectively. Of these women, all had booked for antenatal care, 2 
had a history of fever, none had PPROM and 2 were HIV-positive. 
Only 1 required respiratory support and high care. One mother gave 
birth to twins.
In all the pregnant women blood cultures were positive for LM, 
and all were started on empirical LM cover during the 2 weeks 
Table 2. Laboratory data for the neonates managed at 
Tygerberg Hospital
Investigation Result
Blood glucose (mmol/L), median (IQR) 3.9 (1.5 - 6.2) 
White cell count (× 109/L), median (IQR) 9.9 (3.7 - 21.9)
Haemoglobin (g/dL), median (IQR) 14.0 (12.7 - 15.2) 
Platelet count (× 109/L), median (IQR) 107 (66 - 190)
CRP (mg/L), median (IQR) 137 (107 - 156) 
CSF culture obtained, n (%) 4/13 (30.8)
CSF positive, n (%) 2/4 (50.0)
CSF polymorphs (/µL)), median (IQR) 24.5 (15.8 - 29.3) 
CSF lymphocytes (/µL)), median (IQR) 104 (54.5 - 244.5)
CSF glucose (mmol/L), median (IQR) 2.7 (2.6 - 3.8) 
CSF protein (g/L), median (IQR) 1.7 (1.6 - 1.9) 
IQR = interquartile range; CRP = C-reactive protein; CSF = cerebrospinal fluid.
Table 3. A comparison between neonates managed at TBH and those managed at peripheral hospitals
Managed at TBH (N=13) Managed outside TBH (N=10) p-value
Age at presentation (days), median (IQR) 0 (0 - 3) 0.5 (0 - 1) 0.6622
Weight (kg), median (IQR) 2.2 (1.5 - 2.4) n/a -
CSF culture obtained, n (%) 4/13 (30.8) 9/10 (90.0) 0.005
CSF positive, n (%) 2/4 (50.0) 2/9 (22.2) 0.320
Length of stay (days) (IQR) 5 (2 - 15) 20.5 (14.5 - 23) 0.013
Outcome death, n (%) 8/13 (61.5) 0/10 (0) 0.002
Blood glucose (mmol/L), median (IQR) 3.9 (1.5 - 6.2) n/a
White cell count (× 109/L), median (IQR) 9.9 (3.7 - 21.9) 8.0 (4.0 - 14.8) 0.952
Haemoglobin (g/dL), median (IQR) 14.0 (12.7 - 15.2) 16.0 (14.4 - 17.8) 0.072
Platelet count (× 109/L), median (IQR) 107 (66 - 190) 239 (167 - 254) 0.004
CRP (mg/L), median (IQR) 137 (107 - 156) 64 (36 - 97) 0.013
TBH = Tygerberg Hospital; IQR = interquartile range; n/a = not applicable; CSF = cerebrospinal fluid; CRP = C-reactive protein.
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prior to delivery. All their infants were empirically managed with 
ampicillin following delivery, although none were clinically unwell 
and all had negative blood cultures. Two of the infants had negative 
CSF cultures, and lumbar puncture was not performed in the other 
two. All the mothers and their infants were discharged alive.
There were 3 cases of LM in children aged 3 months - 13 years. In 
2009 LM was cultured from the CSF of a 9-month-old child with a 
ventriculoperitoneal shunt infection, and in 2013 a 2-year-old child 
admitted following near-drowning subsequently cultured LM on 
blood culture. Both patients developed signs of meningitis and sepsis 
and were diagnosed with LM infection ~2 weeks after admission. The 
third case, in 2015, was in a previously healthy 10-year-old who was 
diagnosed with LM meningitis. Immunodeficiency screens in this 
patient were all negative.
We identified an additional 84 cases of LM in adults and children 
in the Metro West region between 2006 and 2016 via the NHLS 
central data warehouse. Of these cases, 29 were in children aged 
<13  years, with 27 occurring in infants aged <3 months. All these 
patients were aged <1 month of age and all cultures were taken 
between 0 and 2 days of age. 
The incidence rates of LM for TBH and surrounding areas 
including Metro West are summarised in Table 5. Incidences across 
all areas were low except for the TBH NICU.
Discussion
The objective of this study was to determine whether empirical 
ampicillin is indicated outside the neonatal period. There were only 
13 cases of LM infection in infants aged <3 months (all in neonates 
<1 month old) at TBH during the 11-year study period, while only 
3 sporadic cases occurred beyond 3 months of age. These results 
support the restriction of ampicillin for the treatment of severe 
infection, including meningitis, to neonates ≤1 month of age, 
especially when stocks of ampicillin are limited.
The incidence of neonatal LM at TBH from 2006 to 2016 
(0.04/1 000 live births) is in keeping with the low incidence rates in 
developed countries, namely the UK (0.05/1 000 live births), The 
Netherlands (0.01/1 000) and the USA (0.09/1 000).[1] The incidence 
of LM causing severe infection may be an underestimate, as not all 
neonates are treated in district health facilities where blood and CSF 
cultures are available. Infants who died before contact with healthcare 
facilities would also not have been among the cases captured. 
Empirical treatment of sepsis before obtaining cultures may also 
decrease the laboratory yield of LM.
The increased number of cases in 2015 could be explained by the 
increased cases seen in the Cape Metro at this time.[15]
In our study the presence of maternal fever or PPROM was not 
very well documented, as in the Baragwanath Hospital study. [12] 
All the neonatal cases presented within the first 10 days of life 
with features of severe sepsis, similar to the presenting symptoms 
of infants described in the Baragwanath and Durban studies.[12,13] 
Similarly, in a neighbouring Western Cape health region (Western 
Metro), all the cases of LM occurred within the first 2 days of life. 
The majority of our cases also presented in the early neonatal period 
(within the first week), with only two cases of late-onset infection 
occurring between 7 and 10 days. In our study, 50% of the neonates 
who underwent lumbar puncture had a CSF culture positive for LM. 
This is in contrast to 100% in the Durban study.[13] The significance of 
this finding is limited, however, as in our study CSF was not obtained 
from the majority of the neonates because they were considered 
too unstable to tolerate a lumbar puncture. The CSF of patients in 
our study revealed a lymphocyte predominance, in contrast to the 
polymorphonuclear predominance in the Durban study.[13] The 
age pattern did not differ between the neonates treated in regional 
hospitals who did not require referral to the tertiary hospital and 
those who were managed at TBH (all were <10 days of age); however, 
the former were more likely to have a CSF culture obtained, although 
only 22.2% were culture-positive.
In our study, the mortality rate for neonates diagnosed with LM 
managed at TBH was 62.0%. These neonates had risk factors known 
to be associated with a poor outcome: clinical presentation within 
the first few days of life, requiring admission to an intensive care 
unit, and prematurity. These findings are in keeping with previous 
studies[5,13] highlighting the mode of presentation and high mortality 
rate of early-onset infection.[12] The paradox of the zero mortality rate 
(0%) of the neonates treated in regional hospitals in contrast to those 
treated in the tertiary care hospital can probably be explained by 
the transfer of severely ill neonates to the tertiary care hospital. HIV 
infection has been shown to be a risk for LM infection[21,22] and this 
has been evident in the recent outbreak in SA.[23] In our study, 30.8% 
of the infants infected with LM were HIV exposed (one infected); this 
is two-fold higher than the current HIV prevalence rates of 16 - 18% 
in pregnant women in the Western Cape.[24] Although our numbers 
are small, the higher HIV prevalence rate in our study may indicate 
that neonates whose mothers are HIV-positive have an increased risk 
of LM infection.[23]
Table 5. Listeria monocytogenes infection incidence rates per 
area, 2006 - 2016
Area Incidence, n/N (/1 000)
TBH: Live births 3/75 297 (0.04)
TBH neonatal high care: Admissions 3/22 614 (0.13)
TBH NICU: Admissions 12/5 134 (2.3)
Winelands: Live births 6/67 383 (0.09)
Overberg: Live births 3/30 056 (0.1)
Metro East: Live births 14/309 204 (0.05)
Metro West: Live births 27/390 162 (0.07)
TBH = Tygerberg Hospital; NICU = neonatal intensive care unit.
Table 4. A comparison between neonates born at TBH and those transferred to TBH
Born at TBH (N=3) Transferred in (N=10)
Age (days), median (IQR) 0 (0 - 0) 1.5 (0 - 3)
Presented in hospital, % 100 60.0
Outcome death, n (%) 2/3 (66.7) 6/10 (60.0)
Blood glucose (mmol/L), median (IQR) 1.4 (1.2 - 1.6) 4.9 (2.4 - 6.3)
White cell count (× 109/L), median (IQR) 6.7 (4.6 - 8.3) 12.72 (4.4 - 23.0)
Platelet count (× 109/L), median (IQR) 190 (148.5 - 390) 102.5 (60 - 146)
CRP (mg/L), median (IQR) 87 (43.5 - 97) 142 (116.8 - 163)
TBH = Tygerberg Hospital; IQR = interquartile range; CRP = C-reactive protein.
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Four of the neonates were admitted from home via the emergency 
unit in their respective hospitals directly to the TBH NICU. The rest 
presented soon after delivery, before discharge from hospital, with 
nearly half (44.4%) presenting on the day of delivery. None of the 
neonates treated for LM were admitted via the paediatric medical 
casualty department or via the neonatal high-care ward that serves 
neonates referred from regional hospitals. This probably reflects the 
severity of illness, requiring direct intensive care admission.
Early-onset infection with LM in the first 7 days of life is 
associated with overwhelming sepsis and a high mortality rate.[5] 
The typical presentation of late-onset LM is a term neonate born to 
an asymptomatic mother who presents with nonspecific illness and 
laboratory indicators of meningitis.[25] The two TBH patients with 
late-onset infection presented at 9 and 10 days of age and CSF was not 
obtained from either; however, both died. Other cases that fitted this 
profile may have been missed if blood or CSF had not been drawn for 
culture or if cultures were falsely negative.
In an international review of LM cases, only 0.1% (5 out of 524 
cases) occurred between 1 and 3 months of age.[1] Together with 
the results of our study, this supports limiting the use of ampicillin, 
in combination with a third-generation cephalosporin, to neonates 
<1 month of age suspected of having severe infection and requiring 
meningitis cover. This would be in keeping with international 
guidelines and recommendations from other developed countries 
such as Canada,[26] the USA[27] and The Netherlands.[28] This policy 
would be appropriate where stocks of ampicillin are limited, as has 
been experienced in the local health system. For infants and children 
outside this age range, using a third-generation cephalosporin as a 
single agent would cover the most common bacteria in this age group. 
This is currently the drug of choice for children presenting with 
possible severe infection to clinics run by Integrated Management 
of Childhood Illnesses[29]-trained nurses and to our paediatric 
emergency centre.
An additional argument for the use of ampicillin in neonates 
being treated for severe infection is that ampicillin will also cover 
cephalosporin-resistant Enterococcus.[4] Enterococcus is an uncommon 
cause of bacteraemia and meningitis and a more common cause of 
urinary tract infection (UTI).[30] It is also more likely to present in a 
neonate or infant who has been hospitalised for a long time.[31] In our 
setting, Enterococcus bloodstream infection usually follows a UTI and 
is a cause of nosocomial bloodstream infections.[32] We specifically 
wanted to identify the need for ampicillin in community-acquired 
infections presenting in the first 3 months of life and therefore did not 
include enterococcal infections in our data collection and analysis. 
However, medical staff should be aware of the possible need for 
additional cover with ampicillin in the setting of UTI and nosocomial 
infections in young infants.
Subsequent to our study, SA experienced a nationwide Listeria 
outbreak with a total of 820 laboratory-confirmed cases reported to 
the National Institute for Communicable Diseases between January 
2017 and 23 January 2018. Of the cases 13% were from the Western 
Cape, of which 13 were neonates managed at TBH. Outcome data 
available for 134 cases show a 45% mortality rate. Similar to the 
findings in our study, there is an almost equal distribution between 
adult and neonatal cases, with 39% of cases being in neonates aged 
<28 days, with 96% of these patients <6 days old. Only 25% of 
LM-infected females aged 15 - 49 years were pregnant.[23]
Study limitations
This study has a number of limitations. Firstly, the number of 
infections caused by LM may have been underestimated, as we 
included only neonates and children who were culture-positive. 
Neonates and children treated for severe infection may have had 
false-negative cultures for LM, i.e. an insufficient sample or a blood 
sample for culture drawn after first antibiotic dose. Stillborn fetuses 
and infants who died before cultures could be taken may also have 
had a severe LM infection. Secondly, the retrospective nature of 
the study may have resulted in some cases being missed. These 
limitations could have led us to underestimate the incidence of 
infection, but not its clinical presentation.
Conclusions
Given that none of our cases of LM in neonates over the past 11 years 
presented after 10 days of age, it would be safe to limit empirical 
ampicillin prescription to neonates presenting with presumed sepsis 
at this tertiary care hospital to the first month of life. Similar previous 
data from other regions of the country support this change in policy, 
but before the recommendation is accepted nationwide, studies in 
other tertiary and regional hospitals should be conducted to confirm 
this finding. In an outbreak situation, as was being experienced 
in SA at the time of writing, it would be important to consider a 
change in protocol to provide empirical cover for older children and 
adult patients presenting with signs and symptoms compatible with 
LM infection, until the epidemiology of the outbreak is adequately 
described.
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